全球肥胖症治療藥物市場分析 是由出版商RNCOS E-Services Pvt. Ltd.在2011年06月所出版的。
這份英文市場調查報告書包含85 Pages 價格從美金1000起跳。
肥胖症不止在先進國家，即使在低所得及中所得國家也非常流行。肥胖症的人口，在2008年約五億人，預計到2015年將達到約7億人，一般認為治療藥物市場，到2014年末將成長到25億美金的規模。
本報告提供全球肥胖症治療藥物市場相關調查分析，市場的趨勢與實際成果，已上市/開發階段的各種治療藥物的評估，每個地區的開發狀況等等，同時包含主要企業簡介，為您概述為以下內容。
第1章 分析師的見解
第2章 調查手法
第3章 全球肥胖症的流行
第4章 市場的趨勢
- 肥胖症患病率的增加
- 龐大的研發費用支出
- 策略性合作
- 新興的治療方法
第5章 全球肥胖症治療藥物市場:產業的實際成果
- 市場概要
- 主要的治療藥物
- Orlistat/Xenical
- Meridia
- Acomplia
- Alli
- 未來的肥胖症治療藥物開發平台
- Liraglutide
- Armodafinil
- Sulfamethoxazole/trimethoprim
- IHBG-10
- 賣得最好的減肥補充劑
第6章 地區水準的開發
第7章 競爭情勢
- F Hoffmann-La Roche Ltd
- Abbott Laboratories
- AstraZeneca Plc
- Sanofi-Aventis SA
- Takeda Pharmaceutical Company Limited
圖表
Abstract
The obesity epidemic has been disseminating among developed countries as well
as low-income and middle-income countries. The main factor responsible for the
propagation of this disease in the middle and low income countries is the
result of new dietary habits and sedentary ways of life, fuelling chronic
diseases, and premature mortality. As per WHO, the obese population is
forecasted to reach around 700 Million by the end of 2015 from around 500
Million in 2008, which signifies immense opportunities for the players
entering this market. Consequently, the obesity drug market is expected to be
worth US$ 2.5 Billion by the end of 2014.
According to our report “Global Obesity Drug Market Analysis”, one
of the main factors that has been surging the revenue is the heavy R&D
spending on the discovery of new drugs. During the last few years, various
obesity drugs have been banned by the FDA and various other regulatory bodies
on grounds of safety reasons. The drugs have been identified causing serious
side effects, such as liver damage, early stage heart disease, and many more.
As a result, the drug manufacturers are heavily investing on the research and
development of new drugs, which poses minimum or no side effects on the
patients.
Further, North America and Europe are expected to be largest obesity drug
market as they constitute some of the fattest nations such as, the US, Mexico,
Germany etc. As obesity and related morbidities have huge medical costs
associated with it, the governments in these regions have been taking rigorous
steps to control this pandemic, which further fuels the growth of the market
in these regions.
Our report also provides information of the key competitors in the market
along with their business information and areas of expertise. The report shows
a highly concentrated structure of the market, with the top players dominating
the market. It provides segment level analysis of the industry along with the
emerging trends that may shape up with the betterment of economic conditions.
The research will help consultants, industry analysts, and vendors to get
in-depth knowledge of the current, past, and future performance of the
industry. The report provides an extensive research on the recent trends of
the global obesity drug market along with an impartial analysis considering
the impact of financial crisis on its performance.
Table of Contents
1. Analyst View
2. Research Methodology
3. Understanding Obesity Pandemic
4. Market Trends
- 4.1. Increasing Prevalence of Obesity
- 4.2. Heavy R&D Spending
- 4.3. Strategic Alliances
- 4.4. Emerging New Treatments
- 4.4.1. Drug Combos
- 4.4.2. Cannabinoids
- 4.4.3. Information and Communication Technologies
5. Global Obesity Drug Market: Industry Performance
- 5.1. Market Overview
- 5.2. Major Drugs
- 5.2.1. Orlistat/Xenical
- 5.2.2. Meridia
- 5.2.3. Acomplia
- 5.2.4. Alli
- 5.3. Future Obesity Drug Pipeline
- 5.3.1. Liraglutide
- 5.3.2. Armodafinil
- 5.3.3. Sulfamethoxazole/trimethoprim
- 5.3.4. IHBG-10
- 5.4. Top Selling Weight-Loss Supplements
6. Regional Level Developments
- 6.1. North America
- 6.1.1. US
- 6.1.2. Mexico
- 6.1.3. Canada
- 6.2. Latin America
- 6.3. Europe
- 6.3.1. UK
- 6.3.2. France
- 6.3.3. Germany
- 6.4. Asia-Pacific
- 6.4.1. Australia
- 6.4.2. New Zealand
- 6.4.3. India
- 6.4.4. China
- 6.5. Middle East and Africa
- 6.5.1. UAE
- 6.5.2. Qatar
- 6.5.3. Saudi Arabia
- 6.5.4. South Africa
7. Competitive Landscape
- 7.1. F Hoffmann-La Roche Ltd
- 7.2. Abbott Laboratories
- 7.3. AstraZeneca Plc
- 7.4. Sanofi-Aventis SA
- 7.5. Takeda Pharmaceutical Company Limited
List of Figures:
- Figure 4-1: Global - Obese Population Aged above 15 Years (Million), 2008
& 2015
- Figure 5-1: Global - Obesity Drug Market (Billion US$), 2010-2014
- Figure 5-2: Global - Orlistat/Xenical Sales (Million US$), 2008-2010
- Figure 5-3: Global - Meridia Sales (Million US$), 2008-2010
- Figure 5-4: Global - Acomplia Sales (Million US$), 2007 & 2008
- Figure 5-5: Global - Alli Sales (Million GBP), 2008-2010
- Figure 6-1: US - Obesity Prevalence (%), 2009 & 2015
- Figure 6-2: Mexico - Overweight and Obesity Prevalence (%), 2000 & 2006
- Figure 6-3: Canada - Obese Population (Million), 2007-2009
- Figure 6-4: Brazil - Obesity Prevalence (%), 2002-03 & 2008-09
- Figure 6-5: UK - Obesity Prevalence (%), 2009, 2015 & 2025
- Figure 6-6: UK - Obesity Prevalence in Children (%), 2007-08 to 2009-10
- Figure 6-7: France - Obesity Prevalence (%), 2003, 2006 & 2009
- Figure 6-8: Germany - Overweight and Obesity Prevalence (%), 2008
- Figure 6-9: Australia - Obesity Prevalence (%), 2006-07 & 2007-08
- Figure 6-10: Australia - Obesity Prevalence in Children Aged 7-15 Years
(%), 1985, 1995 & 2007
- Figure 6-11: New Zealand - Obesity Prevalence (%), 1997, 2003 & 2007
- Figure 6-12: India - Overweight Prevalence (%), 2005 & 2015
- Figure 6-13: India - Obesity Drug Market (Billion INR), 2009-2011
- Figure 6-14: Qatar - Obesity Prevalence (%), 2003, 2005 & 2010
List of Tables:
- Table 3-1: Risk of Co-morbidities based on BMI Levels
- Table 6-1: US - Obesity Prevalence by Age Group (%), 2009
- Table 6-2: Mexico - Overweight and Obesity Prevalence in Children by Age
Group (%), 2006
- Table 6-3: Brazil - Obesity Prevalence by Age Group (%), 2008-09
- Table 6-4: Australia - Cost of Obesity (Billion US$), 2008-09
- Table 6-5: South Africa - Overweight Prevalence in Top Cities (%)
- Table 7-1: F Hoffmann-La Roche Ltd - SWOT Analysis
- Table 7-2: Abbott Laboratories - SWOT Analysis
- Table 7-3: AstraZeneca Plc - SWOT Analysis
- Table 7-4: Sanofi-Aventis SA - SWOT Analysis
- Table 7-5: Takeda Pharmaceutical Company Limited - SWOT Analysis
|
